Creatinine-Body Weight Ratio as a Predictor of Hepatic Steatosis in Patients With Metabolic Syndrome
Metabolic syndrome is a major global health burden characterized by a clustering of metabolic abnormalities including central obesity, hypertension, dyslipidaemia, and impaired glucose metabolism. Recent modelling data indicated that the worldwide prevalence of metabolic syndrome doubled between 2000 and 2023, reaching approximately 31% among women and 26% among men, with an estimated 1.54 billion adults affected globally [1].
In the Middle East and North Africa region, the prevalence of metabolic syndrome-associated liver disease has been reported to reach nearly 40% in the general population [2].
Hepatic steatosis, now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) following the 2023 multi-society Delphi consensus statement, encompasses a spectrum of conditions ranging from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma [3]. The global prevalence of NAFLD/MASLD has been estimated at approximately 32.4%, with a steadily increasing trend over the past two decades [4].
Given that early identification of hepatic steatosis may prevent progression to advanced liver disease, there is a clinical need for simple, inexpensive, and readily available screening biomarkers [5].
Serum creatinine is traditionally used as a marker of renal function; however, because creatinine is generated as a metabolic end-product of skeletal muscle, its circulating concentration also reflects total body muscle mass. Adjusting serum creatinine for body weight yields the creatinine-to-body weight (Cr/BW) ratio, which has been proposed as a simple surrogate marker of relative muscle mass and sarcopenic obesity [6].
In a landmark longitudinal cohort of 13,728 participants, participants in the lowest Cr/BW quartile demonstrated a significantly higher cumulative incidence of NAFLD compared with the highest quartile, confirming Cr/BW as an independent predictor of fatty liver disease [7].
Reduced skeletal muscle mass and sarcopenia are increasingly recognized as contributors to insulin resistance and metabolic dysfunction, both of which are central to the pathogenesis of MASLD [8]. A bidirectional relationship between the Cr/BW ratio and NAFLD has been demonstrated in a longitudinal study of 9,662 participants followed for four years, suggesting that low muscle mass and hepatic steatosis may reinforce one another [9].
Furthermore, a recent cross-sectional study of 1,492 participants found that the Cr/BW ratio independently predicted the severity of hepatic steatosis as measured by controlled attenuation parameter, with a threshold of 1.01 identifying high-risk individuals [10].
Despite this emerging evidence, published data on the predictive value of the Cr/BW ratio for hepaticsteatosis specifically in patients with metabolic syndrome remain limited. Most existing studies were conducted in East Asian populations and focused on NAFLD without selecting for the metabolic syndrome phenotype. Therefore, this study aims to evaluate the predictive value of the Cr/BW ratio for hepatic steatosis in patients with metabolic syndrome attending Assiut University Hospital.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged ≥18 years. • Patients fulfilling criteria of metabolic syndrome
Metabolic syndrome will be diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Presence of at least three of the following:
Waist circumference:
- Men>102 cm
- Women>88 cm
- Triglycerides ≥150 mg/dL or treatment for hypertriglyceridemia.
HDL cholesterol:
- Men<40 mg/dL
- Women<50 mg/dL
- Blood pressure ≥130/85 mmHg or current antihypertensive treatment.
- Fasting blood glucose ≥100 mg/dL or treatment for diabetes mellitus. • Patients willing to participate and provide informed consent.
Exclusion Criteria:
Chronic liver disease other than MASLD.
- Viral hepatitis B or C.
- Significant alcohol intake.
- Hepatotoxic drug use.
- Chronic kidney disease stage 4 or 5.
- Acute kidney injury.
- Malignancy.
- Pregnancy.
- Active infection or inflammatory disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
study group
Patients with metabolic syndrome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
creatinine-to-body weight ratio in patients with metabolic syndrome
Time Frame: baseline
|
creatinine-to-body weight ratio in patients with metabolic syndrome
|
baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Creatinine-Body Weight Ratio
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.